Impact News +++ Micron Isn't Nvidia. It's Time to Take Your Foot Off the Gas with MU Stock. (Barchart) +++ MICRON Aktie +3,06%

REDHILL BIOPHARMA Aktie

>REDHILL BIO Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>REDHILL BIOPHARMA Aktie

Name:

REDHILL BIOPHARMA ADR

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US7574683014 / A40MF2

Symbol/ Ticker:

2RH (Frankfurt) / RDHL (NASDAQ)

Kürzel:

FRA:2RH, ETR:2RH, 2RH:GR, NASDAQ:RDHL

Index:

Webseite:

https://www.redhillbio.co..

Profil:

Marktkapitalisierung:

4.45 Mio. EUR

Unternehmenswert:

1.96 Mio. EUR

Umsatz:

EBITDA:

Nettogewinn:

Gewinn je Aktie:

Schulden:

0.92 Mio. EUR

Liquide Mittel:

3.41 Mio. EUR

Operativer Cashflow:

Bargeldquote:

0.21

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

REDHILL BIOPHARMA, REDHILL BIO

Letzte Datenerhebung:

30.05.26

>REDHILL BIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 5.19 Mio. St.

Frei handelbar: 88.91%

Leerverk. Aktien: 0.42%

Rückkaufquote: -

Mitarbeiter: 13

Umsatz/Mitarb.: 0.02 Mio. EUR

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 1.19

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -37.54%

Eigenkaprendite: -

>REDHILL BIO Peer Group

Gesundheit

>REDHILL BIO Chart & Kurs - NASDAQ

>REDHILL BIO News

23.04.26 - 05:01	Insiderhandel: Chief Operating Officer verkauft Aktien von Redhill Biopharma im Wert von 1574 USD (Insiderkauf)
	Raday, Gilead - Vorstand - Tag der Transaktion: 2026-04-06...

15.12.25 - 13:01	RedHill Biopharma′s Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells (PR Newswire)
	Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic cells persisting over time, even with combination therapy1 Studies show that sphingosine......

01.12.25 - 20:12	RedHill Biopharma regains Nasdaq stockholders’ equity compliance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.12.25 - 13:03	RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders′ Equity Requirement (PR Newswire)
	TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market LLC ("Nasdaq") that......

04.11.25 - 16:24	Redhill Biopharma: Aktie steigt nach juristischem Sieg gegen Kukbo/n (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.11.25 - 15:33	RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement (PR Newswire)
	RALEIGH, N.C. and TEL-AVIV, Israel, Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd......

22.10.25 - 22:51	RedHill Biopharma Receives Nasdaq Staff Determination Notification (PR Newswire)
	On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1) Following RedHill's transaction......

06.10.25 - 14:03	RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® (PR Newswire)
	The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months, plus a minimum of $1.3 million in......

29.09.25 - 17:12	Gericht bestätigt 10-Millionen-Dollar-Urteil: Aktie von RedHill Biopharma schießt in die Höhe (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.09.25 - 13:03	RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights (PR Newswire)
	Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in the Bayer-supported Phase 2 combination study of opaganib and darolutamide in advanced prostate......

01.07.25 - 18:01	RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer (PR Newswire)
	Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation Precision medicine approach: The 60-patient Phase 2 study uses the PCPro™ lipid biomarker......

13.05.25 - 13:03	RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill′s $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win (PR Newswire)
	Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement, following the New York Supreme Court's approximately $8.25 million plus legal fees and costs summary judgment in favor of RedHill -- The New York Supreme Court dismissed all Kukbo's......

28.04.25 - 13:06	RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 (PR Newswire)
	Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants This patent grant......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Also denk bei allem, was dich in Kummer versetzt, daran, folgenden Leitsatz anzuwenden: Nicht nur ist das kein Unglück, sondern es tapfer zu tragen ist ein Glück. - Mark Aurel

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram